BNIP3 and digestive system infectious disorder: We demonstrate that BBM treatment is effective in limiting SARS-CoV-2-induced disruption of primary intestinal monolayers (Figure 4(A,B)), as well as preventing intestinal infection with either SARS-CoV-2 pseudovirus bearing the ancestral spike protein (Figure 3(I,J)) or SARS-CoV-2 Omicron subvariants BA.2 (Figure 5(D,F)) and BA.5 (Figure 5(E,G)), in a BNIP3-dependent manner (Figure 5(B,C)).